NASDAQ:PIRS Stock Quote
13.60
+0.00 (0.00%)
Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on discovering and developing innovative protein-based therapeutics
The company's proprietary Anticalin technology platform is designed to create targeted treatments for a variety of diseases, including cancer and respiratory disorders. By engineering proteins that can bind specifically to disease-related targets, Pieris aims to enhance the efficacy and safety of its therapeutic candidates. The company is actively involved in advancing its pipeline of drug candidates through clinical trials, seeking to address unmet medical needs in the pharmaceutical landscape.